SCHEMBL4411780

SCHEMBL4411780

Brc1[nH]c2ncccc2c1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.50
ADORA1 P30542 1/20 0.50
AURKA O14965 1/20 0.46
PARP1 P09874 1/20 0.46
MAPK13 O15264 1/20 0.46
MAPK12 P53778 1/20 0.46
MAPK11 Q15759 1/20 0.46
MAPK14 Q16539 1/20 0.46
AXL P30530 1/20 0.43
PADI4 Q9UM07 1/20 0.43
TYMP P19971 1/20 0.42
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
LOXL3 P58215 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6246075 0.81 MAPK14 (0.66) ADORA2AADORA1AURKAPARP1MAPK13
SCHEMBL28322523 0.79 ADORA2A (0.50) ADORA2AADORA1AURKAPARP1MAPK13
SCHEMBL858414 0.79 IMPDH2 (0.50) ADORA2AADORA1AURKAPARP1MAPK13
SCHEMBL1780573 0.79 MAPK13 (0.59) ADORA2AADORA1AURKAPARP1MAPK13
SCHEMBL857451 0.77 ADORA2A (0.48) ADORA2AADORA1AURKAPARP1MAPK13
SCHEMBL29953690 0.76 ADORA2A (0.47) ADORA2AADORA1AURKAPARP1MAPK13
SCHEMBL29952292 0.76 ADORA2A (0.50) ADORA2AADORA1AURKAPARP1MAPK13
SCHEMBL31710926 0.75 LRRK2 (0.48) AURKAPARP1AXLCCNB2CDK1
SCHEMBL28329874 0.73 AXL (0.47) ADORA2AADORA1AURKAPARP1AXL
SCHEMBL2284222 0.71 MAPK13 (0.54) ADORA2AADORA1MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517872-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-14 US disclosed
US-7517872-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-14 US disclosed
US-7517872-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-14 US disclosed
US-20080206191-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2008-08-28 US disclosed
US-20080206191-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2008-08-28 US disclosed
US-20080206191-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2008-08-28 US disclosed
WO-2008103637-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-28 WO disclosed
WO-2008103637-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206191-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 ADORA2A 2326/4885ADORA1 2845/4885AURKA 4136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.